It is time to regulate carcinogenic tobacco-specific nitrosamines in cigarette tobacco

Cancer Prevention Research

Volumn 7, Issue 7, 2014, Pages 639-647

  Hecht, Stephen S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; ELECTRONIC CIGARETTE; GLUCURONIDE; NITROSAMINE;

CANCER EPIDEMIOLOGY; CARCINOGENICITY; HUMAN; LUNG ADENOCARCINOMA; NONHUMAN; NOTE; PASSIVE SMOKING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY MECHANISM; SMOKING; TOBACCO; TUBE; UNITED STATES; URINE; LEGISLATION AND JURISPRUDENCE; PREVENTION AND CONTROL;

CARCINOGENS; HUMANS; NITROSAMINES; SMOKING; TOBACCO PRODUCTS;

EID: 84904304817     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-14-0095     Document Type: Note

References (84)

1. United States Department of Health and Human Services. The Health Consequences of Smoking: 50 Years of Progress. A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2014.
2. Magee PN, Barnes JM. The production of malignant primary hepatic tumors in the rat by feeding dimethylnitrosamine. Br J Cancer 1956;10:114-22.
3. Druckrey H, Preussmann R, Ivankovic S, Schmähl D. Organotrope Carcinogen Wirkungen bei 65 verschiedenen N-Nitrosoverbindungen an BD-ratten. Z Krebsforsch Klin Onkol 1967;69:103-201.
4. Preussmann R, Stewart BW. N-nitroso carcinogens. In: Searle C, editor. Chemical carcinogens. 2nd ed., Vol 2. ACS Monograph 182. Washington, DC: American Chemical Society; 1981. p. 643-828.
5. Lijinsky W. Chemistry and Biology of N-nitroso compounds. In: Cambridge monographs on cancer research. Cambridge, UK: Cambridge University Press; 1992. p. 251-403.
6. Bogovski P, Bogovski S. Animal species in which N-nitroso compounds induce cancer. Int J Cancer 1981;27:471-4. (Pubitemid 11159732)
7. Peto R, Gray R, Brantom P, Grasso P. Effects on 4080 rats of chronic ingestion of N-nitrosodiethylamine or N-nitrosodimethylamine: a detailed dose-response study. Cancer Res 1991;51:6415-51.
8. Wynder EL, Graham EA. Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma. A study of six hundred and eighty-four proved cases. J Am Med Assoc 1950;143:329-36.
9. Doll R, Hill AB. Smoking and carcinoma of the lung: a preliminary report. Br Med J 1950;ii:739-48.
10. Boyland E, Roe FJC, Gorrod JW. Induction of pulmonary tumours in mice by nitrosonornicotine, a possible constituent of tobacco smoke. Nature 1964;202:1126.
11. Hoffmann D, Raineri R, Hecht SS, Maronpot R, Wynder EL. Effects of N′-nitrosonornicotine and N′-nitrosoanabasine in rats. J Natl Cancer Inst 1975;55:977-81.
12. Hecht SS, Chen CB, Ohmori T, Hoffmann D. Comparative carcinogenicity in F344 rats of the tobacco specific nitrosamines, N′-nitrosonornicotine and 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res 1980;40:298-302. (Pubitemid 10140152)
13. Hecht SS, Chen CB, Hirota N, Ornaf RM, Tso TC, Hoffmann D. Tobacco specific nitrosamines: formation from nicotine in vitro and during tobacco curing and carcinogenicity in strain A mice. J Natl Cancer Inst 1978;60:819-24. (Pubitemid 8331120)
14. International Agency for Research on Cancer. Smokeless tobacco and tobacco-specific nitrosamines. In: IARC monographs on the evaluation of carcinogenic risks to humans. Vol. 89. Lyon, FR: IARC; 2007. p. 421-583.
15. Hecht SS. Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem Res Toxicol 1998;11:559-603. (Pubitemid 28285583)
16. 6-methylguanine formation in Clara cells and induction of pulmonary neoplasia in the rat by 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanone. Cancer Res 1990; 50:3772-80.
17. Rivenson A, Hoffmann D, Prokopczyk B, Amin S, Hecht SS. Induction of lung and exocrine pancreas tumors in F344 rats by tobacco-specific and Areca-derived N-nitrosamines. Cancer Res 1988;48:6912-7. (Pubitemid 19012226)
18. Roethig HJ, Munjal S, Feng S, Liang Q, Sarkar M, Walk RA, et al. Population estimates for biomarkers of exposure to cigarette smoke in adult U.S. cigarette smokers. Nicotine Tob Res 2009;11:1216-25.
19. Vogel RI, Carmella SG, Stepanov I, Hatsukami DK, Hecht SS. The ratio of a urinary tobacco-specific lung carcinogen metabolite to cotinine is signi ficantly higher in passive than in active smokers. Biomarkers 2011;16:491-7.
20. Xia Y, Bernert JT, Jain RB, Ashley DL, Pirkle JL. Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in smokers in the United States: NHANES 2007-2008. Biomarkers 2011;16:112-9.
21. Stepanov I, Upadhyaya P, Feuer R, Jensen J, Hatsukami DK, Hecht SS. Extensive metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in smokers. Cancer Epidemiol Biomarkers Prev 2008;17:1764-73.
22. Appleton S, Olegario RM, Lipowicz PJ. TSNA levels in machine-generated mainstream cigarette smoke: 35 years of data. Regul Toxicol Pharmacol 2013;66:197-207.
23. Stepanov I, Knezevich A, Zhang L, Watson CH, Hatsukami DK, Hecht SS. Carcinogenic tobacco-specific N-nitrosamines in U.S. cigarettes: three decades of remarkable neglect by the tobacco industry. Tob Control 2012;21:44-8.
24. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008;22:659-61. (Pubitemid 351348146)
25. Balbo S, James-Yi S, Johnson CS, O'Sullivan G, Stepanov I, Wang M, et al. (S)-N′-Nitrosonornicotine, a constituent of smokeless tobacco, is a powerful oral cavity carcinogen in rats. Carcinogenesis 2013;34:2178-83.
26. Stoner GD, Adams C, Kresty LA, Hecht SS, Murphy SE, Morse MA. Inhibition of N′-nitrosonornicotine-induced esophageal tumorigenesis by 3-phenylpropyl isothiocyanate. Carcinogenesis 1998;19:2139-43. (Pubitemid 29010253)
27. National Institute of Environmental Health Sciences and National Institutes of Health. National Toxicology Program [cited 2014 Mar 12]. Available from: http://ntp.niehs.nih.gov.
28. Hoffmann D, Hecht SS, Ornaf RM, Wynder EL. N′-nitrosonornicotine in tobacco. Science 1974;186:265-7.
29. Hecht SS, Ornaf RM, Hoffmann D. N′-nitrosonornicotine in tobacco: analysis of possible contributing factors and biologic implications. J Natl Cancer Inst 1974;54:1237-44.
30. National Academy of Sciences - National Research Council Academy of Life Sciences. The health effects of nitrate, nitrite and n-nitroso compounds. Washington, DC: National Academy Press, 1981.
31. Hecht SS, Chen CB, Ornaf RM, Jacobs E, Adams JD, Hoffmann D. Reaction of nicotine and sodium nitrite: formation of nitrosamines and fragmentation of the pyrrolidine ring. J Org Chem 1978;43:72-6. (Pubitemid 8335053)
32. Morgan WT, Reece JB, Risner CH, Bennett CB, Midgett CH, Johnson KS, et al. A collaborative study for the determination of tobacco specific nitrosamines in tobacco. Beitrage zur Tabakforsch Intl 2004; 21:192-203. (Pubitemid 39499590)
33. Wu W, Ashley DL, Watson CH. Simultaneous determination of five tobacco-specific nitrosamines in mainstream cigarette smoke by isotope dilution liquid chromatography/electrospray ionization tandem mass spectrometry. Anal Chem 2003;75:4827-32. (Pubitemid 37139784)
34. International Agency for Research on Cancer. Tobacco smoke and involuntary smoking. In: IARC monographs on the evaluation of carcinogenic risks to humans. Vol. 83. Lyon, FR: IARC; 2004. p. 33-1413.
35. Wu W, Zhang L, Jain RB, Ashley DL, Watson CH. Determination of carcinogenic tobacco-specific nitrosamines in mainstream smoke from U.S.-brand and non-U.S.-brand cigarettes from 14 countries. Nicotine Tob Res 2005;7:443-51. (Pubitemid 41418717)
36. Ashley DL, Beeson MD, Johnson DR, McCraw JM, Richter P, Pirkle JL, et al. Tobacco-specific nitrosamines in tobacco from U.S. brand and non-U.S. brand cigarettes. Nicotine Tob Res 2003;5:323-31. (Pubitemid 36764027)
37. Kim HJ, Shin HS. Determination of tobacco-specific nitrosamines in replacement liquids of electronic cigarettes by liquid chromatographytandem mass spectrometry. J Chromatogr A 2013;1291:48-55.
38. Goniewicz ML, Knysak J, Gawron M, Kosmider L, Sobczak A, Kurek J, et al. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tob Control 2013;23:133-9.
39. Stepanov I, Carmella SG, Briggs A, Hertsgaard L, Lindgren B, Hatsukami DK, et al. Presence of the carcinogen N′-nitrosonornicotine in the urine of some users of oral nicotine replacement therapy products. Cancer Res 2009;69:8236-40.
40. Al Ali R, Rastam S, Ibrahim I, Bazzi A, Fayad S, Shihadeh AL, et al. A comparative study of systemic carcinogen exposure in waterpipe smokers, cigarette smokers and non-smokers. Tob Control 2013 Sep 2. [Epub ahead of print].
41. Radwan G, Hecht SS, Carmella SG, Loffredo CA. Tobacco-specific nitrosamine exposures in smokers and nonsmokers exposed to cigarette or waterpipe tobacco smoke. Nicotine Tob Res 2013;15:130-8.
42. Kassem NO, Daffa RM, Liles S, Jackson SR, Kassem NO, Younis MA, et al. Children's exposure to secondhand and thirdhand smoke carcinogens and toxicants in homes of hookah smokers. Nicotine Tob Res 2014 Mar 3. [Epub ahead of print]
43. Ashley DL, O'Connor RJ, Bernert JT, Watson CH, Polzin GM, Jain RB, et al. Effect of differing levels of tobacco-specific nitrosamines in cigarette smoke on the levels of biomarkers in smokers. Cancer Epidemiol Biomarkers Prev 2010;19:1389-98.
44. Upadhyaya P, Kenney PMJ, Hochalter JB, Wang M, Hecht SS. Tumorigenicity and metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) enantiomers and metabolites in the A/J mouse. Carcinogenesis 1999;20:1577-82. (Pubitemid 29385448)
45. Carmella SG, Ming X, Olvera N, Brookmeyer C, Yoder A, Hecht SS. High throughput liquid and gas chromatography-tandem mass spectrometry assays for tobacco-specific nitrosamine and polycyclic aromatic hydrocarbon metabolites associated with lung cancer in smokers. Chem Res Toxicol 2013;26:1209-17.
46. Carmella SG, Akerkar S, Hecht SS. Metabolites of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in smokers' urine. Cancer Res 1993;53:721-4. (Pubitemid 23077849)
47. Shah KA, Karnes HT. A review of the analysis of tobacco-specific nitrosamines in biological matrices. Crit Rev Toxicol 2010;40:305-27.
48. Hecht SS, Carmella SG, Murphy SE, Akerkar S, Brunnemann KD, Hoffmann D. A tobacco-specific lung carcinogen in the urine of men exposed to cigarette smoke. N Engl J Med 1993;329:1543-6. (Pubitemid 23332440)
49. Lackmann GM, Salzberger U, Tollner U, Chen M, Carmella SG, Hecht SS. Metabolites of a tobacco-specific carcinogen in the urine of newborns. J Natl Cancer Inst 1999;91:459-65. (Pubitemid 29128283)
50. Hecht SS. Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer. Carcinogenesis 2002;23:907-22. (Pubitemid 34752946)
51. Milunsky A, Carmella SG, Ye M, Hecht SS. A tobacco-specific carcinogen in the fetus. Prenat Diagn 2000;20:307-10. (Pubitemid 30204163)
52. Goniewicz ML, Eisner MD, Lazcano-Ponce E, Zielinska-Danch W, Koszowski B, Sobczak A, et al. Comparison of urine cotinine and the tobacco-specific nitrosamine metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) and their ratio to discriminate active from passive smoking. Nicotine Tob Res 2011;13:202-8.
53. Bernert JT, Pirkle JL, Xia Y, Jain RB, Ashley DL, Sampson EJ. Urine concentrations of a tobacco-specific nitrosamine carcinogen in the U. S. population from secondhand smoke exposure. Cancer Epidemiol Biomarkers Prev 2010;19:2969-77.
54. Thomas JL, Guo H, Carmella SG, Balbo S, Han S, Davis A, et al. Metabolites of a tobacco-specific lung carcinogen in children exposed to secondhand or thirdhand tobacco smoke in their homes. Cancer Epidemiol Biomarkers Prev 2011;20:1213-21.
55. Yuan JM, Knezevich AD, Wang R, Gao YT, Hecht SS, Stepanov I. Urinary levels of the tobacco-speci fic carcinogen N′-nitrosonornicotine and its glucuronide are strongly associated with esophageal cancer risk in smokers. Carcinogenesis 2011;32:1366-71.
56. Stepanov I, Hecht SS. Tobacco-specific nitrosamines and their N-glucuronides in the urine of smokers and smokeless tobacco users. Cancer Epidemiol Biomarkers Prev 2005;14:885-91. (Pubitemid 40478552)
57. Kavvadias D, Scherer G, Cheung F, Errington G, Shepperd J, McEwan M. Determination of tobacco-specific N-nitrosamines in urine of smokers and non-smokers. Biomarkers 2009;14:547-53.
58. Urban M, Scherer G, Kavvadias D, Hagedorn HW, Feng S, Serafin R, et al. Quantitation of N′-nitrosonornicotine (NNN) in smokers' urine by liquid chromatography-tandem mass spectrometry. J Anal Toxicol 2009;33:260-5.
59. Xia B, Xia Y, Wong J, Nicodemus KJ, Xu M, Lee J, et al. Quantitative analysis of five tobacco-specific N-nitrosamines in urine by liquid chromatography-atmospheric pressure ionization tandem mass spectrometry. Biomed Chromatogr 2013 Oct 11. [Epub ahead of print].
60. Devesa SS, Shaw G, Blot WJ. Changing patterns of lung cancer incidence by histological type. Cancer Epidemiol Biomarkers Prev 1991;1:29-34.
61. Burns DM, Anderson CM, Gray N. Do changes in cigarette design influence the rise in adenocarcinoma of the lung? Cancer Causes Control 2011;22:13-22.
62. Hoffmann D, Rivenson A, Murphy SE, Chung FL, Amin S, Hecht SS. Cigarette smoking and adenocarcinoma of the lung: the relevance of nicotine-derivedN- nitrosamines. JSmokingRelatDisord1993;4:165-89. (Pubitemid 23344039)
63. Thun MJ, Lopez AD, Hartge P. Smoking-related mortality in the United States. N Engl J Med 2013;368:1753.
64. Hoffmann D, Hoffmann I. The changing cigarette, 1950-1995. J Toxicol Environ Health 1997;50:307-64.
65. Counts ME, Hsu FS, Laffoon SW, Dwyer RW, Cox RH. Mainstream smoke constituent yields and predicting relationships from a worldwide market sample of cigarette brands: ISO smoking conditions. Regul Toxicol Pharmacol 2004;39:111-34. (Pubitemid 38388196)
66. International Agency for Research on Cancer. Some non-heterocyclic polycyclic aromatic hydrocarbons and some related exposures. In: IARC monographs on the evaluation of carcinogenic risks to humans, vol. 92. Lyon, FR: IARC; 2010. p. 35-818.
67. Church TR, Anderson KE, Caporaso NE, Geisser MS, Le C, Zhang Y, et al. A prospectively measured serum biomarker for a tobacco-specific carcinogen and lung cancer in smokers. Cancer Epidemiol Biomarkers Prev 2009;18:260-6.
68. Yuan JM, Koh WP, Murphy SE, Fan Y, Wang R, Carmella SG, et al. Urinary levels of tobacco-specific nitrosamine metabolites in relation to lung cancer development in two prospective cohorts of cigarette smokers. Cancer Res 2009;69:2990-5.
69. Yuan J-M, Gao Y-T, Murphy SE, Carmella SG, Wang R, Zhong Y, et al. Urinary levels of cigarette smoke constituent metabolites are prospectively associated with lung cancer development in smokers. Cancer Res 2011;71:6749-57.
70. Yuan JM, Butler LM, Stepanov I, Hecht SS. Urinary tobacco smoke-constituent biomarkers for assessing risk of lung cancer. Cancer Res 2014;74:401-11.
71. Hecht SS, Murphy SE, Stepanov I, Nelson HH, Yuan J-M. Tobacco smoke biomarkers and cancer risk among male smokers in the Shanghai Cohort Study. Cancer Lett 2012;334:34-8.
72. Stepanov I, Sebero E, Wang R, Gao YT, Hecht SS, Yuan JM. Tobacco-specific N-nitrosamine exposures and cancer risk in the Shanghai Cohort Study: remarkable coherence with rat tumor sites. Int J Cancer 2014;134:2278-83.
73. Haiman CA, Stram DO, Wilkens LR, Pike MC, Kolonel LN, Henderson BE, et al. Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med 2006;354:333-42. (Pubitemid 43145058)
74. Burns DM, Dybing E, Gray N, Hecht S, Anderson C, Sanner T, et al. Mandated lowering of toxicants in cigarette smoke: a description of the World Health Organization TobReg proposal. Tob Control 2008; 17:132-41.
75. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
76. Agaku IT, King BA, Dube SR. Current cigarette smoking among adults - United States, 2005-2012. MMWR Morb Mortal Wkly Rep 2014;63:29-34.
77. U. S. Food and Drug Administration. Harmful and potentially harmful constituents in tobacco products and tobacco smoke; established list. Fed Regist 2012;77:20034-7.
78. Stratton K, Shetty P, Wallace R, Bondurant S. Clearing the smoke: assessing the science base for tobacco harm reduction. Institute of Medicine, Washington, DC: National Academy Press; 2001.
79. Institute of Medicine. Scientific standards for studies on modified risk tobacco products. Washington, DC: National Academy Press; 2012.
80. CEBP Focus: Tobacco Research. Cancer Epidemiol Biomarkers Prev 2009;18:3139-348.
81. Leischow S, Zeller M. Research opportunities to inform tobacco product regulation in the United States. Nicotine Tob Res 2012;14:1-74.
82. Ding YS, Zhang L, Jain RB, Jain N, Wang RY, Ashley DL, et al. Levels of tobacco-specific nitrosamines and polycyclic aromatic hydrocarbons in mainstream smoke from different tobacco varieties. Cancer Epidemiol Biomarkers Prev 2008;17:3366-71.
83. O'Connor RJ. Postmarketing surveillance for "modified-risk" tobacco products. Nicotine Tob Res 2012;14:29-42.
84. National Cancer Institute. Risks associated with smoking cigarettes with low machine-measured yields of tar and nicotine. Smoking and tobacco control monograph no. 13. Bethesda, MD: U.S. Dept of Health and Human Services, National Institutes of Health, National Cancer Institute, NIH Pub. No. 99-4645; 2001.